Tag Archives: ARVs

PEPFAR treatment lifeline threatened by weaknesses at receiving end, GAO report says

By on .

A third in a series of reports examining components of treatment provided through the President’s Emergency Plan For AIDS Relief  details how the the program has strengthened and streamlined antiretroviral drug supply planning, procuring and tracking, but also reveals a wide range of weaknesses hindering partner country management of the lifesaving medicines. The United States […]

Researchers, actress agree: Following past lapses, future in TB, HIV prevention promising, challenging

By on .

In the giddy talk of a turning tide and the chance for an “AIDS-free generation,” a look at the recent history of responses to tuberculosis, the science surrounding that disease as it stands now, and what, after a period of premature complacency in the middle of the last century, yet is to be done to […]

Enhanced NIH Funding Vital For Success in Battle Against AIDS

By on .

If there’s any question about the value of U.S. investments in scientific research on HIV/AIDS, Anthony Fauci probably put it to rest today by noting that in the period since HIV first emerged, “we went from a 26-week lifespan to a 40-year-plus life span” for those infected with the virus. Talk about measureable outcomes. That […]

PEPFAR Has "Mandate Without Money," Haitians Have ARVs without Water, Food, Shelter

By on .

A delegation of HIV-positive Haitains recently visited Washington to lobby for robust funding for PEPFAR. Read their compelling stories in this blog, which details how HIV-positive patients have access to HIV drugs but not necessarilly to a glass of water to wash the pills down or food to make the medicines tolerable and effective.

Another Piece of Evidence in the Case for Earlier, Wider Access to ART

By on .

The case for earlier and wider initiation of antiretroviral therapy just keeps getting stronger. First, there’s the increasing solid consensus that initiating ART earlier significantly increases an HIV patient’s chances of survival. Then there’s the fact that initiating ART earlier reduces the number of people needing more costly second-line therapy. We also know that the […]

100th Antiretroviral Drug approved by FDA for PEPFAR

By on .

Federal officials today celebrated the approval of the 100th antiretroviral drug authorized under an expedited regulatory framework created five years ago, as a way to fast-track the delivery of cheap HIV drugs to the developing world through the PEPFAR program. A panel discussion, held at the Pan American Health Organization Headquarters to mark the milestone, […]

In AIDS Progress Report, Next Steps Are Key

By on .

The end of today’s UNAIDS progress report, detailing the latest figures on access to ARVs, is in some ways more important than the beginning. “The Way Forward,” the report’s conclusion, lays out important next steps in the campaign for universal access, at a time when the global economic crisis and questions about sustainability have cast […]

DOTS Not Enough When it Comes to TB in South Africa

By on .

Dr. Robin Wood, director of the Desmond Tutu HIV Centre in Cape Town, has many startling slides to illustrate the astronomical problem of tuberculosis in South Africa—from photos of desperately poor, overcrowded shantytowns in the Western Cape to graphs that document the escalating rates of HIV/TB co-infection in his native country. But there’s one image […]

Cahn Addresses the Latest (Hot-Button) HIV Treatment Topics

By on .

This post is by Center Director Christine Lubinski, reporting from the 2009 IAS conference in Cape Town. Pedro Cahn, president of Huésped Foundation, an Argentinean AIDS organization involved in HIV/AIDS clinical research, prevention and care, offered a refreshingly candid and provocative HIV treatment update as the second plenary speaker at the IAS conference today. Cahn, […]

HIV/TB Co-infection–The Deadly Duo Take Center Stage at IAS

By on .

This post is by Center Director Christine Lubinski, reporting from the 2009 IAS conference in Cape Town. World renowned HIV/TB expert Dr. Gerry Friedland, a professor of medicine at Yale and a member of the Global Center’s Scientific Advisory Committee, opened this morning’s plenary session at the 2009 IAS conference by highlighting important operational research […]